The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
Open accessAbstract
We describe here the identification and properties of SCH-C (SCH 351125), a small molecule inhibitor of HIV-1 entry via the CCR5 coreceptor. SCH-C, an oxime–piperidine compound, is a specific CCR5 antagonist as determined in multiple receptor binding and signal transduction assays. This compound specifically inhibits HIV-1 infection mediated by CCR5 in U-87 astroglioma cells but has no effect on infection of CXCR4-expressing cells. SCH-C has broad and potent antiviral activity in vitro against primary HIV-1 isolates that use CCR5 as their entry coreceptor, with mean 50% inhibitory concentrations ranging between 0.4 and 9 nM. Moreover, SCH-C strongly inhibits the replication of an R5-using HIV-1 isolate in SCID-hu Thy/Liv mice. SCH-C has a favorable pharmacokinetic profile in rodents and primates with an oral bioavailability of 50–60% and a serum half-life of 5–6 h. On the basis of its novel mechanism of action, potent antiviral activity, and in vivo pharmacokinetic profile, SCH-C is a promising new candidate for therapeutic intervention of HIV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Self-citationLiu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,706
Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., et al. (1996) · Science · doi:10.1126/science.273.5283.1856 · Cited by 2,484
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,287
Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., & Doms, R. W. (1996) · Cell · doi:10.1016/s0092-8674(00)81314-8 · Cited by 1,833
Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., & Landau, N. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.621 · Cited by 1,353
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-2-199907200-00002 · Cited by 843
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751
Furtado, M. R., Callaway, D. S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A., Perelson, A. S., & Wolinsky, S. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402102 · Cited by 611
Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist
Simmons, G., Clapham, P. R., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N. C., & Proudfoot, A. E. I. (1997) · Science · doi:10.1126/science.276.5310.276 · Cited by 608
Dragic, T., Trkola, A., Thompson, D. A. D., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090576697 · Cited by 426
Self-citationTransmission of antiretroviral-drug-resistant HIV-1 variants
Yerly, S., Kaiser, L., Race, E., Bru, J.-P., Clavel, F., & Perrin, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12262-6 · Cited by 389
Wu, L., LaRosa, G., Kassam, N., Gordon, C. J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1373 · Cited by 357
Self-citationDoms, R. W., & Moore, J. P. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.f9 · Cited by 296
Self-citationO'Brien, S. J., & Moore, J. P. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17710.x · Cited by 254
Self-citationZhou, Y., Kurihara, T., Ryseck, R.-P., Yang, Y., Ryan, C., Loy, J., Warr, G., & Bravo, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.4018 · Cited by 245
Olson, W. C., Rabut, G. E. E., Nagashima, K. A., Tran, D. N. H., Anselma, D. J., Monard, S. P., Segal, J. P., Thompson, D. A. D., Kajumo, F., Guo, Y., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4145-4155.1999 · Cited by 224
Self-citationChen, C. H., Matthews, T. J., McDanal, C. B., Bolognesi, D. P., & Greenberg, M. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3771-3777.1995 · Cited by 169
Sato, N., Kuziel, W. A., Melby, P. C., Reddick, R. L., Kostecki, V., Zhao, W., Maeda, N., Ahuja, S. K., & Ahuja, S. S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5519 · Cited by 168
New targets for inhibitors of HIV-1 replication
Moore, J. P., & Stevenson, M. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036060 · Cited by 167
Self-citationHuffnagle, G. B., McNeil, L. K., McDonald, R. A., Murphy, J. W., Toews, G. B., Maeda, N., & Kuziel, W. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4642 · Cited by 166
Trkola, A., Ketas, T., KewalRamani, V. N., Endorf, F., Binley, J. M., Katinger, H., Robinson, J., Littman, D. R., & Moore, J. P. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.1876-1885.1998 · Cited by 160
Self-citationSato, N., Kuziel, W. A., Melby, P. C., Reddick, R. L., Kostecki, V., Zhao, W., Maeda, N., Ahuja, S. K., & Ahuja, S. S. (1999) · PubMed · Cited by 156
HIV-1 entry inhibitors: Evading the issue
Michael, N. L., & Moore, J. P. (1999) · Nature Medicine · doi:10.1038/10462 · Cited by 135
Self-citationPalani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Cox, K., Strizki, J., Endres, M. J., & Baroudy, B. M. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015526o · Cited by 105
Self-citationDevelopment and applications of the SCID-hu mouse model
McCune, J. M. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0024 · Cited by 70
Rabin, L. B., Hincenbergs, M., Moreno, M. B., Warren, S., Linquist-Stepps, V. D., DATEMA, R., Charpiot, B., SEIFERT, J. ‐., Kaneshima, H., & McCune, J. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.755 · Cited by 66
Self-citationConnor, R. I., Sheridan, K. E., Lai, C., Zhang, L., & Ho, D. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5306-5311.1996 · Cited by 57
Self-citationKovalev, G., Duus, K., Wang, L., Lee, R., Bonyhadi, M. L., Ho, D. D., McCune, J. M., Kaneshima, H., & Su, L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7555 · Cited by 27
Self-citation
Cited by
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Inhibiting sexual transmission of HIV-1 infection
Shattock, R. J., & Moore, J. P. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro729 · Cited by 505
Self-citationFätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Metadata
- Authors
- Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Tagat, J. R., McCombie, S., Cox, K., Fawzi, A. B., Chou, C.-C., Pugliese-Sivo, C., Davies, L., Moreno, M. E., Ho, D. D., Trkola, A., Stoddart, C. A., Moore, J. P., Reyes, G. R., & Baroudy, B. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-10-16
- Volume
- 98
- Issue
- 22
- Pages
- 12718-12723
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2135739941
- Cited by
- 299
- References
- 34
- FWCI
- 26.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.